C'Ville Pharmaceutical Company Involved with Multi-Million Dollar Merger
Cavion has developed a new class of drug that monitors certain calcium channels in the brain for serious neurological diseases and says this sale is the next big step for treatment.
"Selling the company to a much larger pharmaceutical company helps to achieve in some certain fashion the ability to get the drug continuing to be developed and move forward. It also gets a return for investors,” said Andrew Krause, President of Cavion.
Jazz plans to start a second phase clinical study in essential tremors sometime in 2020.